TickerFacts.

Lantheus Holdings, Inc. (LNTH): Share Repurchases

Annual figures by period end, from SEC filings.

$300.02M
Year ended 2025-12-31
$200.02M
Trailing 12 months to 2026-06-30
+58.7%
3-year compound annual growth
2013-12-31: $106.0K2020-12-31: $02021-12-31: $02022-12-31: $75.00M2023-12-31: $02024-12-31: $100.00M2025-12-31: $300.02M$300.02M
2013-12-31 Share Repurchases (USD) 2025-12-31
Period endedShare RepurchasesChange YoYSource filing
2025-12-31$300.02M+200.0%2026-02-26, From 2025-01-01
2024-12-31$100.00Mn/a2026-02-26, From 2024-01-01
2023-12-31$0-100.0%2026-02-26, From 2023-01-01
2022-12-31$75.00Mn/a2025-02-26, From 2022-01-01
2021-12-31$0n/a2024-02-22, From 2021-01-01
2020-12-31$0n/a2023-02-23, From 2020-01-01
No annual figure between 2013-12-31 and 2020-12-31.
2013-12-31$106.0Kn/a2016-03-02, From 2013-01-01

Share Repurchases at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShare RepurchasesChange YoY
Lantheus Holdings, Inc. (LNTH)2025-12-31$300.02M+200.0%
QuidelOrtho Corp (QDEL)2025-12-28$0n/a
Idexx Laboratories Inc (IDXX)2025-12-31$1.22B+45.4%
Volitionrx Ltd (VNRX)2024-12-31$0-100.0%

Compare LNTH, QDEL, IDXX, VNRX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗